Septerna, Inc. (SEPN) vs Vir Biotechnology, Inc. (VIR)

Septerna, Inc. and Vir Biotechnology, Inc. are both Biotechnology companies. Septerna, Inc. and Vir Biotechnology, Inc. are of similar size ($1.8B and $1.8B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against 1,495.9%. Septerna, Inc. has the higher net margin (−24.5% vs −83.0%) and the lower return on invested capital (−189.0% vs −39.1%). Across the 15 metrics below, Septerna, Inc. leads on 9 and Vir Biotechnology, Inc. on 6.

Valuation

Metric SEPN VIR Biotechnology median
P/E n/m n/m 7.88
P/S 17.20 5.91 11.47
P/B 4.40 1.82 2.52
Price to free cash flow 14.47 n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 13.44 4.15 10.73
Earnings yield (1.43%) (17.31%) (28.84%)
Free cash flow yield 6.91% (11.36%) (23.03%)

Profitability

Metric SEPN VIR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (44.04%) (92.40%) 0.00%
Net margin (24.51%) (83.00%) 0.00%
Free cash flow margin 118.93% (67.17%) 0.00%
Return on equity (6.34%) (26.08%) (57.72%)
Return on assets (4.94%) (20.91%) (49.22%)
Return on invested capital (189.01%) (39.10%) 0.00%

Growth

Metric SEPN VIR Biotechnology median
Revenue growth (TTM) 13,520.11% 1,495.93% 5.64%
EPS growth (last fiscal year) 84.85% 17.49% —
Revenue growth, 5-year CAGR — (2.14%) 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric SEPN VIR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.99 6.04 4.73
Net debt to EBITDA 5.86 1.02 0.96

Dividend

Metric SEPN VIR Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric SEPN VIR Biotechnology median
Market cap 1.78b 1.81b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack